Caribou Biosciences

Rachel Haurwitz, Ph.D., President and CEO

Berkeley, CA

(NASDAQ: CRBU)

Virtual Presentation

Caribou Biosciences is a clinical-stage CRISPR genome editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome edited cell therapies. The company is developing a pipeline of genome edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

www.cariboubio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions